Xylo

Psychedelics

PSYLO-400X Clin0 neuropsychiatric condition; PSYLO-300X Clin0 neuropsychiatric condition; PSYLO-500X RD undisclosed

Founded as Psylo in 2021 and rebranded to Xylo Bio in January 2025, the company is advancing precision neurotherapeutics via a novel class of non-hallucinogenic neuroplastogens. Neuroplastogens are non‑hallucinogenic small molecules optimized to activate the 5‑HT₂A receptor and stimulate structural and functional neuroplasticity without the perceptual effects typical of psychedelics. Xylo's lead candidates, particularly XYL‑1001, are moving toward clinical trials for psychiatric and neurological conditions. Backed by seed-stage funding and seasoned leadership, Xylo is emerging as a promising force in next-generation brain medicines.